Dr Toni Choueiri (Dana-Farber Cancer Institute, Boston, USA), Prof Viktor Grünwald (University Hospital Essen, Essen, Germany), Dr Martin Voss (Memorial Sloan Kettering Cancer Center, New York, USA) and Prof Jens Bedke (Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany) share key highlights and real-world perspectives on the latest advances in metastatic renal cell carcinoma (mRCC) presented at ASCO 2026.

The panel explores emerging treatment strategies, including the RADICAL trial evaluating radium-223 plus cabozantinib for patients with bone metastases, and updates from the phase 3 CLEAR trial.

They also discuss important quality-of-life findings and body composition data from the LenCabo study, comparing lenvatinib plus everolimus with cabozantinib after PD-1 inhibitor progression.

Beyond treatment, the conversation highlights the growing role of innovation in patient care covering artificial intelligence-driven biomarkers such as vessel branching patterns, and the use of circulating tumour DNA to better understand disease progression and personalise risk assessment.

Bringing together clinical evidence and practical insights, this discussion reflects how rapidly evolving science is shaping more precise and patient-centred care in advanced kidney cancer.